PL3019242T3 - Kompozycje i sposoby leczenia zaburzeń neuropsychiatrycznych przy zastosowaniu agonisty receptora endoteliny-B - Google Patents
Kompozycje i sposoby leczenia zaburzeń neuropsychiatrycznych przy zastosowaniu agonisty receptora endoteliny-BInfo
- Publication number
- PL3019242T3 PL3019242T3 PL14823205T PL14823205T PL3019242T3 PL 3019242 T3 PL3019242 T3 PL 3019242T3 PL 14823205 T PL14823205 T PL 14823205T PL 14823205 T PL14823205 T PL 14823205T PL 3019242 T3 PL3019242 T3 PL 3019242T3
- Authority
- PL
- Poland
- Prior art keywords
- endothelin
- compositions
- methods
- receptor agonist
- neuropsychiatric disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Marine Sciences & Fisheries (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361843702P | 2013-07-08 | 2013-07-08 | |
| US201361902935P | 2013-11-12 | 2013-11-12 | |
| EP14823205.1A EP3019242B1 (en) | 2013-07-08 | 2014-07-08 | Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist |
| PCT/US2014/045748 WO2015006324A2 (en) | 2013-07-08 | 2014-07-08 | Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3019242T3 true PL3019242T3 (pl) | 2021-02-08 |
Family
ID=52280704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14823205T PL3019242T3 (pl) | 2013-07-08 | 2014-07-08 | Kompozycje i sposoby leczenia zaburzeń neuropsychiatrycznych przy zastosowaniu agonisty receptora endoteliny-B |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10561704B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3019242B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6928450B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN113384701A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014287427B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016000431A8 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3171883C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2825101T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3019242T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015006324A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102458399B (zh) | 2009-04-30 | 2014-04-23 | 美国中西部大学 | centhaquin的新制药用途 |
| BR112020022395A2 (pt) * | 2018-05-03 | 2021-04-13 | Midwestern University | Alterações em receptores de endotelina em seguida a hemorragia e ressuscitação por centaquina |
| US20240207356A1 (en) * | 2022-12-26 | 2024-06-27 | Pharmazz, Inc. | Composition and method for wound healing and repair of damaged nerves |
| WO2024222663A1 (zh) * | 2023-04-26 | 2024-10-31 | 拜西欧斯（北京）生物技术有限公司 | 多肽及其应用 |
| US20250000934A1 (en) | 2023-06-28 | 2025-01-02 | Pharmazz, Inc. | Lyophilized sovateltide-based injectable formulation and method for preparation thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3954987A (en) | 1972-12-22 | 1976-05-04 | Sandoz, Inc. | 2-Alkyl-4-substituted amino-quinazolines and nitrates thereof in the treatment of myocardial shock |
| US3983121A (en) | 1974-07-01 | 1976-09-28 | Council Of Scientific And Industrial Research | 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof |
| DE2557784C2 (de) | 1975-12-22 | 1986-04-17 | Hoechst Ag, 6230 Frankfurt | Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate |
| US4761417A (en) | 1982-05-14 | 1988-08-02 | Maroko Peter R | Compounds, compositions and method of treatments for improving circulatory performance |
| US5055470A (en) | 1989-06-01 | 1991-10-08 | Bristol-Myers Squibb Co. | Method of treatment of ischemia in brain |
| US5922681A (en) | 1992-09-14 | 1999-07-13 | Warner-Lambert Company | Endothelin antagonists |
| US20040063719A1 (en) | 1998-08-26 | 2004-04-01 | Queen's University At Kingston | Combination therapy using antihypertensive agents and endothelin antagonists |
| US6545048B1 (en) * | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| SE0004455D0 (sv) * | 2000-12-01 | 2000-12-01 | Milos Pekny | Method for neuron regeneration in the central nervous system |
| US6573285B2 (en) | 2000-12-21 | 2003-06-03 | Bristol-Myers Squibb Co. | Method for preventing or treating pain by administering an endothelin antagonist |
| US20030232787A1 (en) | 2001-05-08 | 2003-12-18 | Dooley David James | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
| WO2003009805A2 (en) * | 2001-07-23 | 2003-02-06 | Brigham And Women's Hospital, Inc. | Analgesic methods using endothelin receptor ligands |
| US7030082B2 (en) | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
| US7973064B2 (en) | 2001-11-27 | 2011-07-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating an opiate analgesic |
| US7351692B2 (en) | 2002-06-19 | 2008-04-01 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating the antipyretic action of a nonopioid analgesic |
| CN1729012B (zh) | 2002-10-24 | 2013-05-22 | 伊利诺伊大学评议会 | 治疗实体瘤的组合物 |
| DE60335743D1 (de) | 2002-11-20 | 2011-02-24 | Neuronova Ab | Verbindungen und verfahren zur erhöhung der neurogenese |
| WO2008043102A2 (en) | 2006-10-06 | 2008-04-10 | Transition Therapeutics Inc. | Vasoactive intestinal polypeptide compositions |
| CA2646704A1 (en) * | 2006-03-23 | 2007-10-04 | Amylin Pharmaceuticals, Inc. | Endothelin and endothelin receptor agonists in the treatment of metabolic diseases |
| PL2182977T3 (pl) * | 2007-08-21 | 2017-01-31 | Midwestern University | Kompozycje do leczenia udaru lub incydentów mózgowo-naczyniowych za pomocą agonisty receptora endoteliny B |
| CN101374259B (zh) | 2007-08-22 | 2012-08-08 | 华为技术有限公司 | 实现多媒体彩铃和多媒体彩像业务的方法和装置 |
| KR101418941B1 (ko) | 2011-04-04 | 2014-07-15 | 서울대학교병원 | 엔도텔린을 유효성분으로 함유하는 허혈성질환 치료용 조성물 |
-
2014
- 2014-07-08 AU AU2014287427A patent/AU2014287427B2/en active Active
- 2014-07-08 WO PCT/US2014/045748 patent/WO2015006324A2/en not_active Ceased
- 2014-07-08 CN CN202110467579.2A patent/CN113384701A/zh active Pending
- 2014-07-08 EP EP14823205.1A patent/EP3019242B1/en active Active
- 2014-07-08 CA CA3171883A patent/CA3171883C/en active Active
- 2014-07-08 JP JP2016525428A patent/JP6928450B2/ja active Active
- 2014-07-08 CA CA2917325A patent/CA2917325C/en active Active
- 2014-07-08 CN CN201480049491.7A patent/CN105682741A/zh active Pending
- 2014-07-08 ES ES14823205T patent/ES2825101T3/es active Active
- 2014-07-08 BR BR112016000431A patent/BR112016000431A8/pt not_active Application Discontinuation
- 2014-07-08 US US14/903,574 patent/US10561704B2/en active Active
- 2014-07-08 PL PL14823205T patent/PL3019242T3/pl unknown
-
2019
- 2019-12-24 US US16/726,427 patent/US20200353031A1/en not_active Abandoned
-
2020
- 2020-10-26 JP JP2020179020A patent/JP7385924B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105682741A (zh) | 2016-06-15 |
| EP3019242B1 (en) | 2020-08-19 |
| ES2825101T3 (es) | 2021-05-14 |
| CA2917325C (en) | 2023-09-05 |
| EP3019242A2 (en) | 2016-05-18 |
| WO2015006324A3 (en) | 2015-11-05 |
| CN113384701A (zh) | 2021-09-14 |
| CA3171883A1 (en) | 2015-01-15 |
| JP7385924B2 (ja) | 2023-11-24 |
| BR112016000431A8 (pt) | 2018-01-23 |
| AU2014287427A1 (en) | 2016-02-11 |
| US10561704B2 (en) | 2020-02-18 |
| US20160151450A1 (en) | 2016-06-02 |
| CA3171883C (en) | 2024-03-05 |
| AU2014287427B2 (en) | 2019-11-21 |
| JP2016523969A (ja) | 2016-08-12 |
| CA2917325A1 (en) | 2015-01-15 |
| WO2015006324A8 (en) | 2016-01-28 |
| JP2021020945A (ja) | 2021-02-18 |
| US20200353031A1 (en) | 2020-11-12 |
| WO2015006324A2 (en) | 2015-01-15 |
| JP6928450B2 (ja) | 2021-09-01 |
| EP3019242A4 (en) | 2017-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287166A (en) | A pyrazolopyridine derivative with an agonistic effect on the glp-1 receptor | |
| IL260784B (en) | Methods of using fxr agonists | |
| IL261036A (en) | Methods of using fxr agonists | |
| IL244109A0 (en) | Methods and devices for determining focus | |
| LT2970473T (lt) | Dr5 agonisto ir anti-pd-1 antagonisto derinys ir naudojimo būdai | |
| IL289996B1 (en) | Melanocortin-4 receptor (mc4r) agonists for use in the treatment of disorders associated with melanocortin-4 receptor pathways | |
| IL261021A (en) | Methods for using fxr agonists | |
| GB201306434D0 (en) | Methods and apparatus for quantifying inflammation | |
| EP2966975A4 (en) | POLLINATION ENHANCEMENT COMPOSITIONS AND METHOD FOR THEIR USE | |
| IL244356B (en) | Formulations for cgrp receptor antagonists | |
| ZA201505875B (en) | Compositions and methods for treating and repairing tendons | |
| PL3019242T3 (pl) | Kompozycje i sposoby leczenia zaburzeń neuropsychiatrycznych przy zastosowaniu agonisty receptora endoteliny-B | |
| ZA201801736B (en) | Progesterone receptor antagonist dosage form | |
| EP2968550A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | |
| EP3046468A4 (en) | Methods and compositions for imaging disorders using polyspecific agents |